Initiation (new start) criteria: Non-formulary tofacitinib 11 mg extended release (Xeljanz XR) will be covered on the prescription drug benefit when the following criteria are met:

1. Prescriber is a rheumatologist and patient has a diagnosis of rheumatoid arthritis/inflammatory arthritis
   - Patient has tried and failed/intolerant to as least 1 of the following:
     - Methotrexate
     - Hydroxychloroquine
     - Sulfasalazine
     - Leflunomide
   - Patient has had previous trial of Xeljanz immediate release (5 mg twice daily) with documented concerns about adherence to twice daily dosing
   - Patient is not currently taking any other medications dosed more than one time a day

2. Prescriber is a rheumatologist and patient has a diagnosis of psoriatic arthritis
   - Patient has tried and failed/intolerant to or has contraindication to methotrexate (methotrexate not required if patient has dactylitis [inflammation of finger or toe])
   - Patient has had previous trial of Xeljanz immediate release (5 mg twice daily) with documented concerns about adherence to twice daily dosing
   - Patient is not currently taking any other medications dosed more than one time a day

3. Prescriber is a gastroenterologist and patient has a diagnosis of ulcerative colitis
   - Patient has tried and failed/intolerant to at least one of the following
     - Infliximab product
     - Adalimumab product (criteria based)
   - Patient has had previous trial of Xeljanz immediate release (5 mg twice daily) with documented concerns about adherence to twice daily dosing
   - Patient is not currently taking any other medications dosed more than one time a day
Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

Tofacitinib 11 mg Extended Release (Xeljanz XR)

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously:

1. Prescriber is a rheumatologist and patient has a diagnosis of rheumatoid arthritis/inflammatory arthritis
   - Patient has had previous trial of Xeljanz immediate release (5 mg twice daily) with documented concerns about adherence to twice daily dosing
   - Patient is not currently taking any other medications dosed more than one time a day

2. Prescriber is a rheumatologist and patient has a diagnosis of psoriatic arthritis
   - Patient has had previous trial of Xeljanz immediate release (5 mg twice daily) with documented concerns about adherence to twice daily dosing
   - Patient is not currently taking any other medications dosed more than one time a day

3. Prescriber is a gastroenterologist and patient has a diagnosis of ulcerative colitis
   - Patient has had previous trial of Xeljanz immediate release (5 mg twice daily) with documented concerns about adherence to twice daily dosing
   - Patient is not currently taking any other medications dosed more than one time a day